Provectus has initiated a Phase 2c clinical trial of PH-10 for the treatment of mild-to-moderate plaque psoriasis. This multicenter, randomized controlled study is expected to enroll up to 90 patients at four different sites, beginning in late December 2010. The subjects will be randomized sequentially by center to one of four treatment cohorts, and will assess efficacy and safety of topical PH-10 applied once daily.
PH-10 is an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin. It is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. Rose Bengal is a compound that has been in use for nearly thirty years by ophthalmologists to assess damage to the eye. It has also been used as an intravenous diagnostic to detect ailments of the liver.
For more information call (866) 594-5999 or visit www.pvct.com.